Home > Research > Publications & Outputs > Medication and treatment use in primary care pa...
View graph of relations

Medication and treatment use in primary care patients with chronic pain of predominantly neuropathic origin.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Medication and treatment use in primary care patients with chronic pain of predominantly neuropathic origin. / Torrance, N.; Smith, B. H.; Watson, M. C. et al.
In: Family Practice, Vol. 24, No. 5, 10.2007, p. 481-485.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Torrance N, Smith BH, Watson MC, Bennett MI. Medication and treatment use in primary care patients with chronic pain of predominantly neuropathic origin. Family Practice. 2007 Oct;24(5):481-485. doi: 10.1093/fampra/cmm042

Author

Torrance, N. ; Smith, B. H. ; Watson, M. C. et al. / Medication and treatment use in primary care patients with chronic pain of predominantly neuropathic origin. In: Family Practice. 2007 ; Vol. 24, No. 5. pp. 481-485.

Bibtex

@article{3ce2fbe1a2624fb695d162d0bb65c0ab,
title = "Medication and treatment use in primary care patients with chronic pain of predominantly neuropathic origin.",
abstract = "Background. Neuropathic pain is widely recognized as one of the most difficult pain syndromes to treat and presents a significant challenge for pain clinicians and GPs. Methods. The Self-complete Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire, recently validated for identifying pain of predominantly neuropathic origin (POPNO), was sent to 6000 adults identified from general practices in the UK. The questionnaire also contained items about chronic pain identification, medications and treatments received for pain and the pain relief these provided. Results. In total, 1420/3002 (48%) of respondents indicated that they suffered with any chronic pain. These were further categorized as those with chronic pain who were S-LANSS negative [{\textquoteleft}chronic pain (non-POPNO){\textquoteright} group, n = 1179] and those with chronic pain who were S-LANSS positive, indicating the presence of POPNO ({\textquoteleft}chronic POPNO{\textquoteright} group, n = 241). Questions relating to treatments and medications were completed by 88% of the respondents (1244/1420). The chronic POPNO group was more likely to receive multiple pain medications (37% versus 21% took two or more pain medications, P < 0.001) and stronger painkillers [e.g. opioids odds ratio 1.94; 95% confidence interval 1.10, 3.42]. Despite this, they reported less effective pain relief than the non-POPNO chronic pain group. Conclusion. Patients in primary care reporting chronic pain were found generally to obtain incomplete relief from their medication with chronic POPNO patients reporting less relief. It is important that patients with any chronic pain are identified and managed appropriately according to their distinct treatment needs. Keywords. Chronic pain, neuropathic pain, primary care, S-LANSS, treatment.",
keywords = "Chronic pain, neuropathic pain, primary care, S-LANSS, treatment.",
author = "N. Torrance and Smith, {B. H.} and Watson, {M. C.} and Bennett, {Michael I.}",
year = "2007",
month = oct,
doi = "10.1093/fampra/cmm042",
language = "English",
volume = "24",
pages = "481--485",
journal = "Family Practice",
issn = "0263-2136",
publisher = "Oxford University Press",
number = "5",

}

RIS

TY - JOUR

T1 - Medication and treatment use in primary care patients with chronic pain of predominantly neuropathic origin.

AU - Torrance, N.

AU - Smith, B. H.

AU - Watson, M. C.

AU - Bennett, Michael I.

PY - 2007/10

Y1 - 2007/10

N2 - Background. Neuropathic pain is widely recognized as one of the most difficult pain syndromes to treat and presents a significant challenge for pain clinicians and GPs. Methods. The Self-complete Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire, recently validated for identifying pain of predominantly neuropathic origin (POPNO), was sent to 6000 adults identified from general practices in the UK. The questionnaire also contained items about chronic pain identification, medications and treatments received for pain and the pain relief these provided. Results. In total, 1420/3002 (48%) of respondents indicated that they suffered with any chronic pain. These were further categorized as those with chronic pain who were S-LANSS negative [‘chronic pain (non-POPNO)’ group, n = 1179] and those with chronic pain who were S-LANSS positive, indicating the presence of POPNO (‘chronic POPNO’ group, n = 241). Questions relating to treatments and medications were completed by 88% of the respondents (1244/1420). The chronic POPNO group was more likely to receive multiple pain medications (37% versus 21% took two or more pain medications, P < 0.001) and stronger painkillers [e.g. opioids odds ratio 1.94; 95% confidence interval 1.10, 3.42]. Despite this, they reported less effective pain relief than the non-POPNO chronic pain group. Conclusion. Patients in primary care reporting chronic pain were found generally to obtain incomplete relief from their medication with chronic POPNO patients reporting less relief. It is important that patients with any chronic pain are identified and managed appropriately according to their distinct treatment needs. Keywords. Chronic pain, neuropathic pain, primary care, S-LANSS, treatment.

AB - Background. Neuropathic pain is widely recognized as one of the most difficult pain syndromes to treat and presents a significant challenge for pain clinicians and GPs. Methods. The Self-complete Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire, recently validated for identifying pain of predominantly neuropathic origin (POPNO), was sent to 6000 adults identified from general practices in the UK. The questionnaire also contained items about chronic pain identification, medications and treatments received for pain and the pain relief these provided. Results. In total, 1420/3002 (48%) of respondents indicated that they suffered with any chronic pain. These were further categorized as those with chronic pain who were S-LANSS negative [‘chronic pain (non-POPNO)’ group, n = 1179] and those with chronic pain who were S-LANSS positive, indicating the presence of POPNO (‘chronic POPNO’ group, n = 241). Questions relating to treatments and medications were completed by 88% of the respondents (1244/1420). The chronic POPNO group was more likely to receive multiple pain medications (37% versus 21% took two or more pain medications, P < 0.001) and stronger painkillers [e.g. opioids odds ratio 1.94; 95% confidence interval 1.10, 3.42]. Despite this, they reported less effective pain relief than the non-POPNO chronic pain group. Conclusion. Patients in primary care reporting chronic pain were found generally to obtain incomplete relief from their medication with chronic POPNO patients reporting less relief. It is important that patients with any chronic pain are identified and managed appropriately according to their distinct treatment needs. Keywords. Chronic pain, neuropathic pain, primary care, S-LANSS, treatment.

KW - Chronic pain

KW - neuropathic pain

KW - primary care

KW - S-LANSS

KW - treatment.

U2 - 10.1093/fampra/cmm042

DO - 10.1093/fampra/cmm042

M3 - Journal article

VL - 24

SP - 481

EP - 485

JO - Family Practice

JF - Family Practice

SN - 0263-2136

IS - 5

ER -